Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating ...

Arcturus, a new COVID-19 sub-variant ... (With inputs from agencies) WATCH WION LIVE HERE ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a price target of $63.00. Discover outperforming stocks ...

Collectively, these elements underscore Arcturus Therapeutics’ capacity for innovation and market penetration, justifying the Buy rating. ARCT’s price has also changed moderately for the past ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...

Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154 ...

Arcturus has been described as having the usual ... suffering from an "itchy" conjunctivitis or pinkeye, reports Belfast Live. The World Health Organisation (WHO) is also focusing its attention ...

Neda Safarzadeh, Sr. Director, Head of IR, PR & Marketing, Arcturus Therapeutics Holdings Inc., San Diego, CA, USA, Tel: +1-858-900-2682 Arcturus Therapeutics, based ...

Fintel reports that on January 28, 2025, BTIG initiated coverage of Arcturus Therapeutics Holdings (NasdaqGM:ARCT) with a Buy recommendation. As of December 23, 2024, the average one-year price ...